Insider Shareholders with Direct Ownership of Nuvectis Pharma, Inc. (NVCT)
This section provides a comprehensive overview of the insiders with direct ownership of Nuvectis Pharma, Inc. (NVCT). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Nuvectis Pharma, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Ron Bentsur
Chairman & CEO |
700,965 | 0 | 3,266,424 $16.6 Million | 70 |
Nov 15, 2024
Added 0.61%
|
|
Marlio Charles Mosseri
> 10% Shareholder |
231,824 | 0 | 2,612,000 $13.2 Million | 20 |
Dec 13, 2024
Added 0.65%
|
|
Enrique Poradosu
Chief Science & Business Off |
313,270 | 0 | 1,506,319 $7.64 Million | 9 |
Nov 19, 2024
Added 0.13%
|
|
Shay Shemesh
Chief Dev. & Ops. Officer |
316,399 | 0 | 1,493,068 $7.57 Million | 19 |
May 10, 2024
Added 0.07%
|
|
Kenneth Hoberman
Director |
54,000 | 0 | 103,140 $522,919 | 3 |
Jun 13, 2024
Added 22.53%
|
|
Michael J. Carson
Vice President, Finance |
63,373 | 2,755 | 87,918 $445,744 | 3 |
Nov 07, 2024
Reduced 3.04%
|
|
Matthew L. Kaplan
Director |
51,000 | 0 | 83,760 $424,663 | 3 |
Jun 13, 2024
Added 26.37%
|
|
James F Oliviero Iii
Director |
48,000 | 0 | 57,828 $293,187 | 2 |
Jun 13, 2024
Added 34.16%
|